NCT Number: NCT00157963
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension
Looking for future studies?
Notify MeKey information
Age range
20 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients of age 20 70 75 with essential hypertension
- SiDBP 90 ~ 114mmHg at V1 & V2
Exclusion criteria
- Patient has known or suspected secondary hypertension
- Patient has a history of malignant hypertension (SiSBP > 210mmHg)
- Individuals has a known sensitivity or intolerance to HCTZ or any AIIAs, or any sulfonamide-derived drugs.
- Patient has shown significant abnormal laboratory evaluations
Treatment and study plan
Primary outcomes
-
Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipine
Secondary outcomes
-
Safety/Tolerability
Sponsors and collaborators
Lead sponsor
Organon and Co
Industry
Registry information
Official study title
A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients.
Important dates
- Study start
- 2005
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Sep 12, 2005
- Registry last updated
- Aug 15, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
NCT07704697
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsAssess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
NCT07704684
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsA Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
NCT07700875
Cardiovascular Diseases, Essential Hypertension
Jinan, Shangdong, China
View Trial DetailsPhase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
NCT05503953
Cardiovascular Diseases, Essential Hypertension
Seoul, South Korea
View Trial Details